Title: Crafting a Robust Business Model for Orphan Drug Development
Abstract: Human Gene TherapyVol. 22, No. 7 Insight and Intelligence®Crafting a Robust Business Model for Orphan Drug DevelopmentPublished Online:14 Jul 2011https://doi.org/10.1089/hum.2011.2511AboutSectionsView articleView Full TextPDF/EPUB Permissions & CitationsPermissionsDownload CitationsTrack CitationsAdd to favorites Back To Publication ShareShare onFacebookTwitterLinked InRedditEmail View articleFiguresReferencesRelatedDetailsCited byDeveloping Treatments for Rare Diseases on a Shoestring Ana C. Puhl, Sarah Negri, Maggie A.Z. Hupcey, and Sean Ekins16 October 2023 | GEN Biotechnology, Vol. 2, No. 5An Overview of rAAV Vector Product Development for Gene Therapy19 December 2015Business Model Literature OverviewFINANCIAL REPORTING, No. 1 Volume 22Issue 7Jul 2011 InformationCopyright 2011, Mary Ann Liebert, Inc.To cite this article:Crafting a Robust Business Model for Orphan Drug Development.Human Gene Therapy.Jul 2011.781-783.http://doi.org/10.1089/hum.2011.2511Published in Volume: 22 Issue 7: July 14, 2011PDF download
Publication Year: 2011
Publication Date: 2011-07-01
Language: en
Type: article
Indexed In: ['crossref', 'pubmed']
Access and Citation
Cited By Count: 3
AI Researcher Chatbot
Get quick answers to your questions about the article from our AI researcher chatbot